<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645461</url>
  </required_header>
  <id_info>
    <org_study_id>3314</org_study_id>
    <nct_id>NCT02645461</nct_id>
  </id_info>
  <brief_title>Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS</brief_title>
  <acronym>AchALS</acronym>
  <official_title>Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration&#xD;
      and progressive paralysis. Other studies have revealed defects in skeletal muscle even in&#xD;
      absence of motor neuron anomalies, focusing on acetylcholine receptors (AChRs) and supporting&#xD;
      the so-called &quot;dying-back&quot; hypothesis. Outcome of this study will be to understand if the&#xD;
      endocannabinoid palmitoylethanolamide (PEA) can reduce the rundown of AChRs currents in ALS&#xD;
      muscle, and if it can modify ALS patients' clinical and electrophysiological parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome:&#xD;
&#xD;
      Monitoring the efficacy and safety of PEA in the treatment of patients with ALS. Analysis of&#xD;
      AChR currents and description of the composition of AChRs subunits in ALS muscles&#xD;
&#xD;
      Design of the Study:&#xD;
&#xD;
      A randomized controlled blinded study. Patients with sporadic ALS will receive riluzole alone&#xD;
      or riluzole+PEA in order to investigate the clinical and electrophysiological effects of&#xD;
      treatment. The expected number of enrolled patients will be 50.&#xD;
&#xD;
      All patients satisfying the selection criteria will be randomized into two groups: a first&#xD;
      group will be treated only with riluzole, the second group with riluzole associated with PEA&#xD;
      (Normast 600 mg microgranular, 2 sachets/day). The randomization will be done stratifying&#xD;
      patietns according to type of clinical onset (bulbar vs. spinal). The patients will be&#xD;
      enrolled in the Department of Neurology and Psychiatry, University of Rome &quot;Sapienza&quot;.&#xD;
&#xD;
      The visits will be performed at 0 (randomization), 3 and 6 months. At each visit the ALS&#xD;
      Functional Rating Scale-Revised (ALSFRS-R), the percentage of predicted forced vital capacity&#xD;
      (FVC%), the Medical Research Council (MRC) score for muscle strength limited to the right&#xD;
      upper limbs, and the compound muscle action potentials (CMAP) from right ulnar and phrenic&#xD;
      nerves will be assessed. A muscle biopsy will be done at the end of the study. The obtained&#xD;
      results will be compared with those observed in muscle samples from denervated (non-ALS)&#xD;
      control patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in pulmonary capacity of ALS patients at 6 months.</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the percentage of predicted forced vital capacity (FVC %) will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.</measure>
    <time_frame>six months</time_frame>
    <description>Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in muscle strength of ALS patients at 6 months.</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the Medical Research Council (MRC) scale score will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in electrophysiological parameters of ALS patients at 6 months</measure>
    <time_frame>six months</time_frame>
    <description>Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riluzole 50 mg twice daily in ALS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endocannabinoid palmitoylethanolamide (PEA)</intervention_name>
    <description>Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily</description>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
    <other_name>PEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Riluzole 50 mg twice daily</description>
    <arm_group_label>PEA plus Riluzole</arm_group_label>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ALS according to the El-Escorial criteria;&#xD;
&#xD;
          -  Age&gt; 18 years;&#xD;
&#xD;
          -  ALS Functional Rating Scale-Revised (ALSFRS- r) score&gt; 20;&#xD;
&#xD;
          -  Forced Vital Capacity (FVC)&gt; 30%;&#xD;
&#xD;
          -  Treatment with Riluzole.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other diseases motor neurons;&#xD;
&#xD;
          -  Experimental treatments in the previous three months;&#xD;
&#xD;
          -  Pregnant or breast-feeding;&#xD;
&#xD;
          -  Contraindications to the use of riluzole;&#xD;
&#xD;
          -  Patients undergoing tracheostomy, enteral or parenteral supply;&#xD;
&#xD;
          -  Severe psychiatric disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>January 1, 2016</last_update_submitted>
  <last_update_submitted_qc>January 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Maurizio Inghilleri</investigator_full_name>
    <investigator_title>Associated Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 21, 2016</submitted>
    <returned>January 17, 2017</returned>
    <submitted>May 4, 2021</submitted>
    <returned>May 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

